Inhibition of IRAK4 with a specific inhibitor in MYD88L256P mutant ABC-DLBCLs could prevent NF-κB signaling, and inhibited tumor growth when combined with ibrutinib [162]. This evidence concerns the gene NFKB1 and aneurysmal bone cyst.